Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALySSEY: CD70 CAR T Cells for Lymphoma, Myeloma and Solid Tumors
NCT07297160Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cd70-car-t in lymphoma, multiple myeloma (MM), solid tumor and 2 more (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Planned start Jun 2026; status: withdrawn.
02
Drugs
cd70-car-t
03
Conditions
lymphomamultiple myeloma (MM)solid tumorsarcomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07297160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297160.